FTC Warns Novo Nordisk Over Potential Violation in Metsera Bid
The U.S. Federal Trade Commission cautioned Novo Nordisk that its proposed acquisition of Metsera may breach premerger review laws under the Hart-Scott-Rodino Act.
/ 41 items
#PFE↓
Novo Nordisk Cuts Forecast Amid Growing Competition
Novo Nordisk (NVO) lowers 2025 guidance for the fourth time as Wegovy and Ozempic sales slow. New CEO battles Eli Lilly competition while pursuing $10B Metsera acquisition.
Pfizer's Q3: Profit Boosted by Cost Cuts Amidst Major Obesity Acquisition Battle
Pfizer announced strong third-quarter profits, allowing it to raise its 2025 profit forecast. This improvement relies on major cost-cutting efforts, even as the company faces fierce competition and a high-stakes legal fight over the obesity startup Metsera.
Pfizer Sues Metsera and Novo Nordisk Over Breach of Merger Agreement
Pfizer files lawsuit against Metsera, its board, and Novo Nordisk for breaching a merger agreement, claiming illegal interference and regulatory risks in Novo Nordisk’s proposal.
Novo Nordisk Makes $9 Billion Bid for Metsera, Topping Pfizer's Offer
Novo Nordisk offers $77.75/share for Metsera in $9B deal, beating Pfizer's bid. Two-step structure includes immediate $56.50 dividend + milestone payments.
Novo Nordisk Challenges Pfizer's $4.9B Deal for Obesity Startup Metsera
Novo Nordisk makes higher bid for Metsera to outbid Pfizer's $4.9B deal. Learn why this obesity drug startup is sparking a bidding war between pharmaceutical giants.